Adjuvia Therapeutics closed $8 million Series Seed financing to advance ATI-105, a mitochondrial disease therapy, into Phase 1 clinical trials.
- Amount
- $8M
- Stage
- Seed
- Announced
- 29 July 2026
- Lead
- JLO Ventures
- Other investors
- Portfolia Ventures
- Use of funds
- Submit IND application for ATI-105 and begin Phase 1 clinical trials in fall 2026
- Checked
- Amount and date checked against the press source